{"id":"W2139337147","doi":"10.1016/j.jcjd.2014.06.001","title":"Canada Welcomes a Novel Class of Oral Glucose-Lowering Drugs for People with Type 2 Diabetes","year":2014,"lang":"en","type":"editorial","venue":"Canadian Journal of Diabetes","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Diabetes Canada","funders":"","keywords":"Medicine; Metformin; Type 2 diabetes; Diabetes mellitus; Glycemic; Sulfonylurea; Hypoglycemia; Glycated hemoglobin; Insulin; Insulin resistance; Diabetes management; Exenatide; Blood sugar; Internal medicine; Intensive care medicine; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008926781,0.004223518,0.004902727,0.005650733,0.004627508,0.0087497,0.005690489,0.02407119,0.01421185],"category_scores_gemma":[0.02586287,0.001252102,0.005522824,0.003329348,0.002825739,0.003056433,0.001553108,0.02564824,0.007532119],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01491553,"about_ca_system_score_gemma":0.02747088,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.08443366,"about_ca_topic_score_gemma":0.2694075,"domain_scores_codex":[0.9903026,0.0008699122,0.0008100852,0.0005503454,0.006646183,0.0008208479],"domain_scores_gemma":[0.9636441,0.008225126,0.001735899,0.0005404888,0.01788902,0.007965287],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003630944,0.00001718985,0.00002135108,0.0001195416,0.00002034898,0.00005726819,0.000004273692,0.0000175511,0.0000155018,0.00009797027,0.9953663,0.004226419],"study_design_scores_gemma":[0.000319493,0.00007296328,0.0005358004,0.0005326608,0.0001810048,0.0001428794,0.00006347665,0.0001494379,0.00005791108,0.000371444,0.9975383,0.00003447133],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.00005079416,0.009494705,0.00008620016,0.04974044,0.9381692,0.0000505055,0.0001426094,0.00005350131,0.002212029],"genre_scores_gemma":[0.0006338775,0.0167053,0.000277022,0.04954898,0.913048,0.00005511277,0.0001301,0.0000403292,0.01956127],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.9155663,"threshold_uncertainty_score":0.1678844,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006055081229127336,"score_gpt":0.2090055565065253,"score_spread":0.202950475277398,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}